Phase 2 Crohn's Disease and Colitis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have an established diagnosis of Inflammatory Bowel Disease (IBD), either Ulcerative Colitis (UC) or Crohn's Disease (CD).
- People whose bowel disease is currently active, meaning it shows at least mild activity based on recognised scoring measures, or a stool test result showing a calprotectin level above 60 µg/g (a marker of bowel inflammation).
- People whose treating doctor considers them suitable candidates for treatment with adalimumab or risankizumab (confirm with trial site).
- People who are 18 years of age or older.
- People who are willing and able to provide written consent to participate.
- People who have a clinical reason to undergo an endoscopy procedure.
- Women who could potentially become pregnant must have a negative pregnancy test result (either urine or blood) available before participating.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Women who are currently pregnant or breastfeeding.
- Women of premenopausal age who are not using a reliable form of contraception at the time the study imaging agents (adalimumab-680LT and/or risankizumab 800CW) are administered.
- People who have a medical or psychiatric condition that affects their ability to give informed consent.
- People who have previously received a therapy that specifically targets the IL-23 pathway (note: combination therapies targeting both IL-23 and IL-12 are not excluded — confirm with trial site).
- People who have received an anti-TNFα therapy within the 6 weeks before joining the trial.
- People who have previously been treated with adalimumab and have detectable antibodies against it in their system.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +31(0)503612620
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To investigate the feasibility of using dual wavelengths fluorescence molecular endoscopy (FME); To investigate the feasibility of using ex vivo fluorescence molecular imaging (FMI) to detect adalimumab-680LT and risankizumab-800CW signals; Blood pressure; Heart rate; Temperature
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.